Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I think Lauzon was a scam artist cashing in on having a name identical to that of a Mars Inc. executive. Or maybe that wasn't his real name.
I like GLNNF. I own some GLNNF.
I don't like being associated with Oilprice.com, a known shill for P&D operations.
BTW, I was paraphrasing Stephen Hawking: "When I hear of Schrödinger's cat I reach for my gun."
Whenever I see Oilprice.com, I reach for my gun.
Figuratively speaking, of course.
A minor complaint, if I may ...
It's "Canon". Not CANNON. OK?
Canon is a high-tech giant that makes lots of great high-tech stuff and has for decades.
Cannon made towels. It went bankrupt in 2003.
geez
See post #197
bitcoin to 15,000 *this year*? wut?
https://www.cointelegraph.com/news/legendary-bitcoin-trader-masterluc-predicts-15000-bitcoin-this-year
Looks like will close in upper half of previous day's range, which is a good sign usually, though closing in the current day's upper half too is better.
Doubled my position. Mindful of the categorical risks but the story, industry inroads and momentum are too compelling. Not betting the farm. Never bet the farm.
"Penny Green"... very apropos.
In at just under .21, a relative handful of shares, could've bought more but only discovered this one last night so had to consider risks. Pennies are treacherous.
Very relevant article. Doesn't mention US Cobalt and does not appear to be a paid shill.
Can Batteries Cope Without Cobalt?
unless i'm wrong there's only 2 possibilities here
1. The tech is real but development has been held back by an obstinately doddering labrat and majority-holder named Snaper
2. It was a scam from the beginning
Interview with CEO Peter Bakema
CVR Medical: Exciting Proof-of-Concept Results
From a summary of a 2008 General Electric imaging conference:
Phil Bendick received his BS and MS from MIT and his PhD from Stanford University. As an Assistant Professor of Electrical Engineering at Purdue University from 1973 to 1975 he helped establish the Medical Ultrasound Research Laboratory and worked on the development of random signal processing techniques for blood flow detection and measurement, precursors to today’s coded excitation and B-flow techniques.
Bendick became involved with the clinical application of ultrasound with his move in 1976 to the Indiana University Medical Center in Indianapolis, where he established the noninvasive Vascular Laboratories for the University Hospital, Wishard Memorial Hospital (county hospital) and the VA Hospital. In 1986 he moved to William Beaumont Hospital in Royal Oak, Michigan (a suburb of Detroit) as Director of Surgical Research and established the Vascular Laboratory there, where he remains technical director of a department performing over 25,000 non-invasive vascular studies per year.
Dr. Bendick has authored or co-authored over 130 papers in peer reviewed journals and 17 book chapters, and made over 200 presentations at regional, national and international meetings. He was a founding member of the Board of Directors of the Intersocietal Commission for the Accreditation of Vascular Laboratories (ICAVL) and has served on the Board of Governors of the American Institute of Ultrasound in Medicine (AIUM).
In addition to his ongoing clinical activities his research interests encompass a wide spectrum including the natural history and noninvasive evaluation of cardiovascular disease, peripheral vascular applications of ultrasound contrast agents, quantitative measurement of healthcare quality, and the impact of accreditation on healthcare quality.
"Company is taking steps to be current on filings within next few months. Will be releasing more news soon on recent developments. Looking forward to coming months..."
Like listening to muzak. The same tunes over and over.
Clarifying: MetalNRG has nothing to do with us. That's another "US Cobalt", an Australian LTD co. with ops in Nevada. Oops.
I checked out Canon Virginia's Newport News facility on Google Earth. It's not some little suburban outpost in a leased commercial building. It is *gigantic*.
The MetalNRG angle
MetalNRG's investee
An interesting development, might apply to US Cobalt.
New rare-earth extractants
Certainly not cobalt. You might be thinking of perovskite, a form of calcium titanate.
Interesting... First Cobalt in Ontario also announced a private placement, same day. And a private placement announced today with Castle Silver, another cobalt producer.
it's like Groundhog Day here
The article at bottom of pg 7 is interesting. I must note Alvin was later acquitted on basis he apparently thought he was participating in a sting operation, and no proof that he knew otherwise.
http://jfk.hood.edu/Collection/Weisberg%20Subject%20Index%20Files/M%20Disk/Mack%20Gary%20Cover-up/Item%2003.pdf
..... *sigh*...
A lot of noise lately over the world cobalt supply. SciMet would seem like another pie-in-the-sky mining startup except for Wayne Tisdale, if he's the entrepreneurial legend he's made out to be.
One of my "lottery tickets" in my portfolio. I'm wondering if the much-forecast Co price spike hasn't already happened.
Given the approaches, I think it's very likely. One being a DNA/RNA nucleoside analog like gemcitabine but unlike gemcitabine utilizes a kinase found only in cancer cells.
Almost sounds like a sure thing. But keep in mimnd that cancer is uncannily and unpredictably wiley.
That should be this stock's symbol.
SOON
Am I right reading that BWEN has barely 15 million shares outstanding?
Well, we'll see. Still holding my 4K shares for shi*s and giggles.
I looked at the patent. it makes clear that The underlying science and applied technology is not new. What is new for the most part is how the technology is applied.
It lists improvements to the sensor pad (interface between sensor and the patient's skin) to the electronics and/or structure of the sensor itself.
But most important is the innovation of using a triad of sensors in a fixed optimal arrangement (array) as part of a handheld bracket, applied in a specific way to the patient's torso.
Vancouver, BC.
I suppose it's possible - just possible, but only just - that if the CSS really works as well as claimed, early whispers about efficacy might leak from the now-ongoing trials in Philly. Or might already be leaking.
Too much to hope for, maybe. But fun to think about.
There's been some griping elsewhere about CVR not being on the CES 2017 list of exhibitors, despite claims of being "on display" there.
The griping has some justification, but the Carotid Stenotic Scan was graphically and emphatically included as a future beneficiary of Energous' WattUp charging tech. Thus, "displayed".
The big positives here: The joining of Dr. Douglas Weaver, a bigshot in the cardiovascular field, to CVR's Board of Directors; the start in January of clinical device trials by the Jefferson Clinical Research Institute in Philadelphia; and the partnering with the respected and well-established ADCO Circuits.
I also found the US Patent online. Pretty impressive. 9,101,274
If CVR isn't a real deal, then they've managed to fool some pretty smart folks up to this point.
Those Oilprice "articles", such as they are and though informative, I don't find encouraging however.
And why is there no bio of Dr. Weaver on CVR's website? Or did I miss it somehow?
I hope some monumental impending news is indeed driving this.
But I think there are always three different kinds of traders: RNN (or XYZ) shareholders who want to sell, RNN shareholders who won't sell (and maybe want more), and non-holders of RNN who want RNN. (Duh, right?)
That's a 3-legged supply-vs-demand stool that can wobble wildly if one or more legs changes size. A chaotic system with many feedback loops. Something as trivial as an anonymous positive comment overheard from a distinguished diner at a fancy restaurant can nudge it to a tipping point.
My half-ass guess anyway: Maybe a patient or two in the latest phase II displayed a rapid improvement in some metric, too good to be mere placebo, and word got out.
A partnership, merger or buyout would be nice too. ;)
And whatever happened to the autohomogenous mill, or whatever the hell it was called?
Magnatek either works or it doesn't.
If it works, then Alvin et al should have squeezed every bit of output out of it, however marginal, to elicit private placements and/or other financing for perfecting the process.
Why hasn't he?
If it doesn't work, well, that would explain a lot.
It would explain everything.
ctdt's website is pretty much zombie